Breaking Into Medical 'No-Man's Land': Zhongguancun Life Science Park's Innovative Biotechs Flourish with Pioneering Therapies

T cells are extracted and isolated from the patient's blood, and then relevant genes are introduced to equip the T cells with a "GPS" that can precisely target and kill cancer cells. Subsequently, the cells undergo culture expansion, testing, and other steps.About 14 days later, a customized cell and gene therapy drug was born., which will be transported to the hospital and infused back into the patient's body to achieve precise treatment. Nowadays,In the laboratory of Huaxia Yingtai(Beijing)Biotechnology Co., Ltd., an innovative pharmaceutical company, about 6 such "custom-made" cell and gene drugs are generated each month., and invest in the early clinical research of tumors and autoimmune diseases.

In recent years, cell and gene therapies have begun to show remarkable efficacy in the treatment of cancers and rare diseases, becoming a hot area in pharmaceutical development. However, this new therapy still has many shortcomings and challenges. Zhao Xueqiang, co-founder of Huaxia Yingtai(Beijing)Biotechnology Co., Ltd., told reporters that on one hand, current cell therapy drugs on the market mainly target blood cancers and have yet to overcome the more difficult treatment of solid tumors. On the other hand, drugs that require the collection of patients' own cells for "customized" preparation are hard to produce on a large scale, resulting in exorbitant costs, often priced at millions of dollars per injection.

In response to these two major challenges, this innovative pharmaceutical company bravely ventures into "uncharted territory." In攻克实体肿瘤方面，针对恶性程度较高、进展较快的甲胎蛋白阳性胃癌,Huaxia Yingtai's innovative drug product has undergone exploratory clinical trials at Peking University Cancer Hospital for two cases of advanced patients.One of the patients used this therapy for 8 weeks,Gastric Tumor Successfully Reduced by Nearly Half, another patient was evaluated after one month of treatment,The tumor was found to have stopped growing and was effectively controlled.。

Why can the new therapy achieve effective treatment and control of solid tumors? Zhao Xueqiang introduced,The company has adopted its self-developed STAR-T platform in drug design.This new technology has significant advantages over the traditional CAR-T technology in cell therapy. It demonstrates higher sensitivity in recognizing cancer cells, can achieve natural dual targeting, is less prone to exhaustion, and exhibits strong tumor infiltration capabilities.

Recently, at Shanghai Changzheng Hospital,OneA patient who has been suffering from systemic lupus erythematosus for 10 years received a customized cell gene drug from Huaxia Yingtai (Beijing) Biotechnology Co., Ltd., one month later, the evaluation showed that the patient had been basically cured.The drug involved in this clinical study not only demonstrated "remarkable" efficacy but also showed new breakthroughs in safety. Instead of being customized using the patient’s own cells, it is made from healthy donor cells, making it a universal-type cell therapy drug. Zhao Xueqiang stated that currently, related research projects have been initiated at Shanghai Changzheng Hospital. If the preparation of universal-type cell therapy drugs can be achieved, it will significantly reduce the cost of expensive cell and gene therapies and solve the pharmaceutical challenge posed by poor cell quality due to patients' weakened conditions caused by their illnesses.

Huaxia Yingtai, a microcosm of the thriving innovative pharmaceutical companies in Zhongguan Village Life Science Park, is targeting ALS, a disease that has yet to be cured.Innovative pharmaceutical company Shengji Changhua develops gene therapy drugs based on the exclusive target SG001, aiming to achieve long-term effectiveness with a single dose.Recently, the first patient to receive compassionate use in an investigator-initiated clinical study has completed one year of treatment. The rapidly progressing disease prior to treatment has been brought under control.The disease progression tends to stabilize.At the same time, innovative pharmaceutical companies incubated from the innovative achievements of the Beijing Life Science Research Institute, such as Huahui Anjian and Pumu Bio, are also making strides toward treating difficult diseases like hepatitis B and pulmonary fibrosis.